Supernus Pharmaceuticals
SUPN
119 hedge funds and large institutions have $491M invested in Supernus Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
85% more call options, than puts
Call options by funds: $4.93M | Put options by funds: $2.67M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
59% more capital invested
Capital invested by funds: $309M → $491M (+$182M)
45% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 31
11% more funds holding
Funds holding: 107 → 119 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$33.7M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$5.1M |
| 3 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$2.47M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$2.36M |
| 5 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$8.59M |
| 2 |
A
Abingworth
London,
United Kingdom
|
-$5.44M |
| 3 |
MRM
Michael R. Murphy
|
-$4.26M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.41M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$2.55M |
SUPN Hedge Fund Activity: Q1 2015 in Review
119 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2015, worth a combined $491M — up 59% from $309M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SUPN positions and 13 closed out — a net gain of 12 holders — while 45 added to existing stakes and 31 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $33.7M. The largest seller was Ardsley Advisory Partners, cutting an estimated $8.59M.
- 119 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2015, up from 107 in Q4 2014.
- Funds reported $491M of Supernus Pharmaceuticals stock for Q1 2015, up 59% quarter-over-quarter.
- 25 funds opened new Supernus Pharmaceuticals positions in Q1 2015 and 13 closed out, a net change of +12 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2015 was Consonance Capital Management, an estimated $33.7M added.
- The largest Supernus Pharmaceuticals seller in Q1 2015 was Ardsley Advisory Partners, an estimated $8.59M sold.
Based on aggregated 13F filings for Q1 2015.